Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study

Introduction: On the basis of the landmark trial KEYNOTE-189 (KN-189), pembrolizumab plus chemotherapy has become the standard-of-care first-line treatment for patients with advanced nonsquamous NSCLC without oncogenic driver alterations.KN-189 included a selected patient population and lacks extern...

Full description

Bibliographic Details
Main Authors:	Till Wallrabenstein, MD, Maximilian Mamot, MSc, Eveline Daetwyler, MD, David König, MD, Sacha I. Rothschild, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Series:	JTO Clinical and Research Reports
Subjects:	Non–small cell lung cancer Immuno-chemotherapy real-world data Pembrolizumab ECOG PS 2
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364323000486

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323000486

Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study

Internet

Similar Items